Evidence map›Paper›PMID 29844873›Full record

ArticleOncotarget2018

Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3.

Addys González Palomo, Armando López Medinilla, Valeria Segatori, María Del Carmen Barroso, Rances Blanco, Mariano R Gabri, Adriana Carr Pérez, Kalet León Monzón

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. The Role of Sphingolipids in Cancer Immunotherapy.International journal of molecular sciences · 2021
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Addys González PalomoCenter of Molecular Immunology (CIM), Atabey, Playa, Havana, Cuba.
Armando López MedinillaCenter of Molecular Immunology (CIM), Atabey, Playa, Havana, Cuba.
Valeria SegatoriLaboratory of Molecular Oncology, Quilmes National University, Buenos Aires, Argentina.
María Del Carmen BarrosoCenter of Molecular Immunology (CIM), Atabey, Playa, Havana, Cuba.
Rances BlancoCenter of Molecular Immunology (CIM), Atabey, Playa, Havana, Cuba.
Mariano R GabriLaboratory of Molecular Oncology, Quilmes National University, Buenos Aires, Argentina.
Adriana Carr PérezCenter of Molecular Immunology (CIM), Atabey, Playa, Havana, Cuba.
Kalet León MonzónCenter of Molecular Immunology (CIM), Atabey, Playa, Havana, Cuba.
Center of Molecular Immunology (Cuba) · CUNational University of Quilmes · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several Anti-EGFR mAbs are register for the treatment of human cancer. However, their impact on patients overall survival has been limited by tumor resistance.

Indexed as

combined therapymetastasis-modelsNGcGM3signaling pathwaysurvival

Identifiers

PMID29844873
PMCPMC5963610
OpenAlexW2801445761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.